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Summary  
Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the patho-genesis of 
hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however, EGP 
remains constant during administration of gluconeogenic precursors. This study was performed in order to 
determine whether administration of fructose increases EGP in obese NIDDM patients and obese non-diabetic 
subjects. Eight young healthy lean subjects, eight middle-aged obese NIDDM patients and seven middle-aged 
obese non-diabetic subjects were studied during hourly ingestion of 13C fructose (0.3 g · kg fat free mass-1 · h-1) 
for 3 h. Fructose failed to increase EGP (measured with 6,6 2H glucose) in NIDDM (17.7 ± 1.9 µmol · kg fat free 
mass-1 · min-1 basal vs 15.9 ± 0.9 after fructose), in obese non-diabetic subjects (12.1 ± 0.5 basal vs 13.1 ± 0.5 
after fructose) and in lean healthy subjects (13.3 ± 0.5 basal vs 13.8 ± 0.6 after fructose) although 13C glucose 
synthesis contributed 73.2 % of EGP in lean subjects, 62.6 % in obese non-diabetic subjects, and 52.8 % in 
obese NIDDM patients. Since glucagon may play an important role in the development of hyperglycaemia in 
NIDDM, healthy subjects were also studied during 13C fructose ingestion + hyperglucagonaemia (232 ± 9 ng/l) 
and during hyperglucagonaemia alone. EGP increased by 19.8 % with ingestion of fructose + glucagon (p < 
0.05) but remained unchanged during administration of fructose or glucagon alone. The plasma 13C glucose 
enrichment was identical after fructose ingestion both with and without glucagon, indicating that the contribution 
of fructose gluconeogenesis to the glucose 6-phosphate pool was identical in these two conditions. We 
concluded that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in 
NIDDM, obese non-diabetic, and lean individuals; 2) in lean individuals, both an increased glucagonaemia and 
an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs 
without changes in the relative proportion of glucose 6-phosphate production from fructose and from other 
sources (i. e. glycogenolysis + gluconeogenesis from non-fructose precursors). [Diabetologia (1996) 39: 580-
586] 
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In healthy human subjects and in normal dogs, endogenous glucose production (EGP) has been shown not to rise 
when gluconeogenic substrates are infused and gluconeogenesis is increased [1-5]. This constancy of EGP was 
also observed during infusions of lactate [2] or fructose [5] when insulin and glucagon were maintained constant 
by infusions of somatostatin, insulin and glucagon, indicating autoregulation. The mechanisms responsible for 
this autoregulation of EGP may involve inhibition of gluconeogenesis from endogenous substrates [3] and/or of 
glucogenolysis [2] and stimulation of glycogen synthesis [5]. In non-insulin-dependent diabetic (NIDDM) 
patients, EGP is increased and correlates with fasting plasma glucose [6]. Hepatic balance of gluconeogenic 
precursors [7], estimation of hepatic glycogen degradation by in vivo nuclear magnetic resonance spectroscopy 
[8] and assessment of Cori cycle activity [9], all indicate that an increased gluconeogenesis accounts for a 
substantial part of this increase in EGP. It may be hypothesized that a rise in gluconeogenic substrate availability 
[10, 11] secondary to peripheral insulin resistance is responsible for both stimulation of gluconeogenesis and 
EGP. In the first part of this study, we measured the alterations induced by fructose ingestion on whole body and 
hepatic glucose metabolism in young lean healthy control subjects, in middle-aged obese non-diabetic subjects, 
and in middle-aged obese NIDDM patients. 
The second part of this study aimed to assess whether the alterations of the regulation of glucagon secretion 
which are frequently encountered in NIDDM might alter the regulation of EGP during fructose administration. It 
has been shown that glucagon secretion is increased, or inappropriately decreased in NIDDM patients following 
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meals. Moreover, this relative hyperglucagonaemia has been shown to participate in the development of 
hyperglycaemia [12]. We have also shown that amino acids increase EGP when infused together with exogenous 
glucose [13] or during hyperinsulinaemic clamps and that amino acid-induced glucagon secretion plays a pivotal 
role in stimulating EGP in this condition [14]. We therefore assessed the effect of hyperglucagonaemia on 
fructose-induced gluconeogenesis and on EPG in lean healthy subjects. 
Subjects and methods 
Subjects. Eight young healthy human volunteers [four males, four females, age 23.1 ± 0.8 years (mean ± SEM), 
weight 71.7 ± 3.7 kg, height 174.1 ± 1.9 cm, fat free mass (FFM) (determined from skinfold thickness 
measurements [15]) 56.0 ± 3.7 kg] were selected to participate in three protocols. All were in good physical 
health, were not currently taking any medication, and had no family history of diabetes or related disorders. 
Eight middle-aged obese NIDDM patients (four males, four females, mean age 55.5 ± 3.0 years, weight 88.2 ± 
6.8 kg, height 167.4 ± 2.4 cm, FFM 52.6 ± 2.5 kg) and 7 middle-aged obese subjects with normal glucose 
tolerance (assessed with a standard 75-g oral glucose tolerance test) (seven females, mean age 41.1 ± 4.1 years, 
weight 92.8 ± 4.6 kg, height 164.5 ± 2.5 cm, FFM 54.5 ± 3.9 kg were recruited to participate in protocol 1. 
NIDDM subjects were maintained in good metabolic control with oral anti-diabetic agents (mean HbA1c 5.9 ± 
0.9 %) and were not taking any other medication. They discontinued all drug treatment 4 days prior to the study. 
All subjects had maintained a steady body weight for at least 3 months before taking part in the study. They were 
placed on an isocaloric, 50 % carbohydrate diet devoid of foods naturally enriched in 13C during the 3 days 
preceding each study. 
Experimental protocols were approved by the ethical committees of Lausanne and Liège Schools of Medicine. 
General procedures. All experiments began between 07.00 and 09.00 hours after a 10-12-h fast. After having 
voided urine, the subjects lay in the supine position and an indwelling venous cannula was inserted into an 
antecubital vein of one arm. A primed (3000 µg/kg) continuous (30 µg · kg-1 · min-1) infusion of 6,6 2H glucose 
(1 g/l; Isotech Inc., Miamisburg, Ohio, USA) was started at time -180 min and was continued throughout the 6-h 
experiment. A second cannula was inserted into a wrist vein of the contralateral arm and was used to collect 
blood samples periodically between time -30 and 180 min. This hand was placed in a thermostabilized box 
heated to 60°C in order to achieve partial arterialization of venous blood (oxygen saturation 70-80%). 
Respiratory gas exchanges were monitored between -60 and 180 min by continuous flow indirect calorimetry, 
using a ventilated canopy [16]. The air at the inlet and outlet of the canopy was continuously analysed for O2 
(Magnos 3G delta; Hartmann and Braun, Frankfurt, Germany) and CO2 (Uras 3G delta; Hartmann and Braun), 
and the total air flow through the canopy was measured with a digital pneumotachograph (Godart-stathan BV, 
Bilthoven, The Netherlands). Breath samples were collected at intervals for determination of 13CO2. 
Protocol 1: Eight young healthy subjects, seven middle-aged obese non-diabetic subjects, and eight middle-aged 
obese NIDDM patients took part in this protocol. After a 2-h equilibration period, baseline data were collected 
between -60 and 0 min. Subsequently a fructose load (300 mg/kg FFM, dissolved in 50 ml lemon-flavoured 
water) enriched with 1-13C fructose (Isotech Inc.) at 1.113 % 13C was administered orally once every hour until 
time 180 min. It was assumed that the total amount of fructose absorbed during the period 120-180 min was 300 
mg/kg FFM, or 5 mg · kg FFM-1 · min-1. 
The eight healthy subjects studied in protocol 1 also participated in protocols 2 and 3. 
Protocol 2: This protocol was identical to protocol 1 but, in addition, glucagon (Glucagène; Novo Nordisk, 
Copenhagen, Denmark) was infused at a rate of 3 ng · kg-1 · min-1 between 0 and 180 min. 
Protocol 3: This protocol was designed to evaluate the effects of hyperglucagonaemia alone on glucose 
production and oxidation. For this purpose, subjects were infused with glucagon at a rate of 3 ng · kg-1 · min-1 
between 0 and 180 min, but did not receive any fructose. 
Glucose kinetics: Glucose rates of appearance (which were equal to EGP) and of disappearance (GRd) were 
calculated from plasma 6,6 2H enrichment during the periods -30-0 min and 120-180 min. Steele's equations for 
steady-state conditions were used for this purpose [17]. The contribution of gluconeogenesis from fructose to 
EGP (EGP(F)) was calculated during the period 300-360 min from the rate of 13C glucose appearance using the 
equation of Chiasson et al. [18]. Glucose production from sources other than fructose (EGP(non-F)) (i.e. from 
glycogenolysis and gluconeogenesis from lactate, amino acids and glycerol) was calculated as: 
 
 
Substrate oxidation rates. Net carbohydrate oxidation rates were calculated from respiratory gas exchanges and 
urinary nitrogen excretion corrected for changes in blood urea nitrogen [19] using the equations of Livesey and 
Elia [20]. 13C fructose oxidation was calculated as: 
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where breath 13CO2 and infused 13C fructose are expressed in atom % excess (APE) and V CO& 2 in ml/min; FFM 
is fat-free mass in kg and 0.8 is a correction for incomplete recovery of 13CO2 in breath [21]; 0.134 is the ml of 
CO2 produced during oxidation of 1 µmol fructose. Non-oxidative fructose disposal was calculated as: Non-ox 
FD = fructose ingested - 13C fructose ox Non-ox FD represents mainly glucose synthesis from fructose with 
glycogen deposition of the neoformed glucose and de novo lipogenesis from fructose. However, the latter 
process appears to be quantitatively small. 
Analytical procedures. Plasma 6,6 2H glucose was measured by GC-MS (HP) of penta-acetylated glucose in 
electron impact mode, with selected monitoring of m/z 242.1 and 244.1. Plasma 13C glucose was purified by 
HPLC [22] and analysed by isotope ratio mass spectrometry (Roboprep CN/Tracermass; Europa Scientific, 
Crewe, U.K.). Breath 13CO2 was measured by isotope ratio mass spectrometry (Roboprep g/Tracermass; Europa 
Scientific). Plasma insulin (kit from Biodata SpA, Guidonia Montecelio, Italy) and glucagon (kit KGND1; DPC, 
Los Angeles, Calif., USA) were measured by radioimmunoassay. Plasma and urine fructose [23] were measured 
enzymatically. Plasma non-esterified fatty acids were measured colorimetrically using a kit from Wako 
(Freiburg, Germany). Urinary nitrogen was measured with the method of Kjehldahl [24]. 
Statistical analysis 
All data are expressed as mean ± SEM unless stated otherwise. Data were averaged to a single value for periods -
60-0 min (except for glucose kinetics for which the period -30-0 min was considered) and 120-180 min. 
Comparisons between healthy volunteers, obese non-diabetic subjects and obese NIDDM patients were 
performed during each of these two periods with modified analysis of variance and unpaired f-tests. Comparison 
between healthy subjects during protocols 1, 2 and 3 were performed with modified analysis of variance and 
paired f-tests. 
Results 
Basal substrate and hormone concentrations are shown in Table 1. NIDDM patients had a 55 % increase in 
plasma glucose concentration (p < 0.01) and 47 % increase in plasma non-esterified fatty acid concentrations 
(NS), and obese non-diabetic subjects had an 80 % increase in plasma non-esterified fatty acid concentrations 
(NS) vs lean healthy subjects. Net carbohydrate (CHO) oxidation in the basal state averaged 11.4 ± 1.1 µmol · kg 
FFM-1 · min-1 in healthy subjects, 7.8 ± 1.5 µmol · kg FFM-1 · min-1 in obese non-diabetic subjects (NS) and 8.2 · 
0.6 µmol · kg FFM-1 · min-1 in NIDDM patients (p < 0.05 vs lean healthy subjects). Basal EGP was increased by 
33.1 % in NIDDM patients (p < 0.05 vs lean subjects) but not in obese non-diabetic patients compared to lean 
control subjects (Table 2). 
 
Table 1. Plasma glucose, fructose, insulin, glucagon and non-esterified fatty acid concentrations before and 
during fructose administration 
Glucose (mmol/l) Insulin (pmol/l) Non-esterified fatty 
acids (mmol/l) 
Glucagon (ng/l) Fructose (mmol/l)  n 
Basal Fructose Basal Fructose Basal Fructose Basal Fructose Basal Fructose 
Lean 
subjects 8 4.82 ± 0.12 5.16 ± 0.14a 29.9 ± 4.1 47.6 ± 6.1b 0.59 ± 0.11 0.43 ± 0.13b 105 ± 6 103 ± 4 0 ± 0 0.18 ± 0.03c
Obese 
subjects 7 5.02 ± 0.10 5.26 ± 0.13a 56.0 ± 12.9 73.0 ± 13.7 1.06 ± 0.24 0.61 ± 0.13b 78 ±11 61 ± 3 0 ± 0 0.35 ± 0.05cd
Obese 
NIDDM 
patients 8 7.49 ± 0.46e 7.69 ± 0.50e 71.1 ± 12.9d 84.0 ± 15.7 0.87 ± 0.17 0.57 ± 0.15b 78 ± 10 75 ± 10 0 ± 0 0.32 ± 0.15c
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Table 2. Endogenous glucose production (EGP) in the subjects studied 
Basal state Fructose administration  n 
EGP 
(µmol · kg FFM-1 · min-1) 
EGP EGP (F)  
(µmol · kg FFM-1 · min-1) 
EGP (NF) 
Lean subjects 8 13.3 ± 0.5 13.8 ± 0.6 10.1 ± 1.2 3.7 ± 0.9 
Obese subjects 7 12.1 ± 0.5 13.1 ± 0.5 8.2 ± 0.7 4.9 ± 0.8 
Obese NIDDM patients 8 17.7 ± 1.7a 15.9 ± 0.9 8.4 ± 1.2 7.5 ± 0.8b
EGP (F), Gluconeogenesis from fructose; EGP (NF), endogenous glucose production from sources other than fructose ap < 0.05 and bp < 
0.01 vs lean subjects 
 
Effects of fructose ingestion on glucose metabolism in young healthy lean subjects, middle-aged obese non-
diabetic subjects, and middle-aged obese NIDDM patients (protocol 1). The effects of fructose ingestion on 
plasma glucose, fructose, 13C glucose APE and breath 13CO2 APE are shown in Figure 1. Fructose ingestion 
slightly increased plasma glucose and markedly decreased plasma non-esterified fatty acid concentrations in all 
three groups of subjects (Fig. 1; Table 1). Plasma fructose concentrations were slightly higher in obese non-
diabetic subjects than in lean subjects (p < 0.05). EGP(F) was slightly lower in obese non-diabetic and in obese 
NIDDM subjects, but the difference was not significant. EGP was not altered by fructose ingestion although 13C 
glucose synthesis contributed 73.2 % of EGP in lean subjects, 62.6 % in obese non-diabetic subjects, and 52.8 % 
in obese NIDDM patients (Table 2). The stimulation by fructose of net CHO oxidation and the inhibition of net 
lipid oxidation were similar in obese and lean subjects. In NIDDM patients, the stimulation of CHO oxidation 
and of fructose oxidation and the inhibition of net lipid oxidation were blunted, resulting in a marked increase in 
net non-oxidative CHO disposal and in a slight increase in non-oxidative fructose disposal (Table 3). This non-
oxidative fructose disposal indicates an increased rate of net glycogen deposition and/or de novo lipogenesis. 
 
Fig.1. Plasma glucose, fructose and 13C glucose APE and breath 13CO2 APE in young lean subjects ( ), 
middle-aged obese non-diabetic subjects ( ) and middle-aged obese patients with NIDDM ( ). 
Fructose was administered once every hour starting at time 0 min 
 
 
Table 3. Effects of fructose administration on net carbohydrate oxidation (CHO ox), fructose oxidation (13C F 
ox) non-oxidative fructose disposal (non ox F d) and net lipid oxidation (Lox) 
 n Increase in CHO oxb 
(µmol · kg FFM-1 · 
min-1) 
13CFox (µmol · kg 
FFM-1 · min-1) 
Non ox F d (µmol · 
kg FFM-1 · min-1) 
Decrease in Loxb (mg · 
kg FFM-1 · min-1) 
Lean subjects 8 7.5 ± 0.8 10.7 ± 0.6 17.0 ± 0.6 0.40 ± 0.09 
Obese subjects 7 7.3 ± 1.4 9.7 ± 0.6 18.1 ± 0.6 0.41 ± 0.15 
Obese NIDDM patients 8 4.7 ± 1.0a 8.7 ± 0.2a 19.0 ± 0.2a 0.26 ± 0.14a
a p < 0.05 vs C; b after subtraction of basal CHO ox and Lox 
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Effects of hyperglucagonaemia + fructose on glucose metabolism in healthy lean subjects (protocol 2). Infusion 
of glucagon increased plasma glucagon concentrations by 108.0 % (Table 4). When fructose was ingested during 
hyperglucagonaemia, EGP increased by 19.8 % (Fig. 2) (p < 0.001). However, plasma 13C glucose enrichment 
(which is a reflection of the enrichment of the intrahepatic glucose 6-phosρhate) was identical with or without 
glucagon (Fig. 3), indicating that both glucose synthesized from fructose and glucose originating from other 
sources (i. e. glycogenolysis   and  gluconeogenesis  from  other  precursors) contributed equally to this increase 
in EGP. As a consequence of the increase in EGP, plasma glucose and insulin were increased by 29.2 (p < 0.01) 
and 133.3 % (p < 0.001), respectively (Table 4). 13C fructose oxidation, non-oxidative fructose disposal, and the 
increment in net CHO ox (Fig. 4), and net non-oxidative CHO disposal  (6.3 ± 1.8 vs 7.3 ± 2.5 µmol · kg-1 ·         
mm-1) were identical without or with hyperglucagonaemia. 
Effects of hyperglucagonaemia alone on glucose metabolism in healthy lean subjects (protocol 3). Infusion of 
glucagon increased plasma glucagon concentration in the same range as in protocol 2. However, EGP did not 
increase (Fig. 2) and net CHO oxidation tended to increase (Fig. 4) (p = 0.14) while lipid oxidation decreased 
slightly (p = 0.052). Slight rises in plasma glucose levels (from 4.8 ± 0.1 to 5.4 ± 0.1 mmol/l, p < 0.01) and 
insulin levels (from 28.5 ± 5.6 to 35.3 ± 3.6 pmol/l, p < 0.01) were also observed (Table 4). 
 
Fig.2. EGP (□), gluconeogenesis from fructose (GNGF)  and EGP from sources other than fructose 
(EGP(NF) ) in lean healthy subjects in the basal state and during fructose administration (F), fructose 
administration and glucagon infusion (F + G) and glucagon infusion alone (G). * p < 0.001 vs basal 
 
 
Table 4. Plasma glucose, insulin and glucagon concentrations in healthy subjects during baseline (time -30-0 
min) and during administration of fructose, fructose + glucagon, or glucagon 
Glucose (mmol/l) Insulin (pmol/l) Glucagon (ng/l)  
-30-0 min 120-180 min -30-0 min 120-180 min -30-0 min 120-180 min 
Fructose 4.81 ± 0.12 5.16 ± 0.14a 29.9 ± 4.1 47.6 ± 6.1b 105 ± 6 103 ± 4 
Fructose + glucagon 4.61 ± 0.09 5.96 ± 0.23b 34.4 ± 4.8 80.3 ± 10.7b 112 ± 5 233 ± 9c
Glucagon 4.81 ± 0.09 5.41 ± 0.10a 28.5 ± 5.6 35.3 ± 3.6 107 ± 4 210 ± 26c
n = 8 for all measurements, ap < 0.05 vs baseline; bp < 0.01 vs baseline; cp < 0.001 vs baseline 
 
Fig. 3. Plasma 13C glucose APE during administration of fructose ( ) or fructose + glucagon ( ) in lean 
healthy subjects 
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Fig.4. CHO ox (□), fructose oxidation (F ox ), and non-fructose carbohydrate oxidation (NF CHO ox ) in 
lean healthy subjects in the basal state and during fructose administration (F), fructose administration and 




Obese NIDDM subjects had an increased basal EGP [6, 9], the mechanisms of which remain unidentified. It has 
been suggested that an increased hepatic lipid oxidation may promote gluconeogenesis and secondarily enhance 
hepatic glucose production [25-28]. In the present study, our obese patients with normal glucose tolerance had 
increased concentrations of plasma non-esterified fatty acids and increased lipid oxidation rate. They also had 
higher than normal plasma insulin concentrations, suggesting insulin resistance. Their basal EGP was normal 
however, indicating that other factors are involved in the increased basal EGP of NIDDM patients. 
Fructose ingestion failed to increase EGP in lean individuals, obese non-diabetic subjects, and obese patients 
with NIDDM. Gluconeogenesis was nonetheless a major pathway of 13C fructose disposal, as indicated by a 
significant increase in plasma 13C glucose APE. This process appeared to be stimulated to the same extent in 
both groups of subjects. The slight rise in plasma glucose and insulin concentrations induced by fructose may 
possibly have contributed to inhibit glycogenolysis and hepatic glucose output. However, it has been 
demonstrated that EGP does not increase in healthy humans infused with fructose even when plasma insulin and 
glucagon are maintained at constant levels by infusions of somatostatin, insulin and glucagon; since plasma 
glucose was also constant in these experiments, it indicated autoregulation of hepatic glucose production in 
healthy humans [5]. 
An increased glycogen synthesis has been shown to participate in the autoregulation of hepatic glucose 
production in healthy lean subjects [5] and is therefore likely to also function in obese NIDDM subjects. Non-
oxidative fructose disposal, which corresponds to glycogen accretion from neoformed glucose [5] and de novo 
lipogenesis [29] were identical in lean subjects, obese non-diabetic subjects and obese patients with NIDDM. 
This suggests that stimulation of glycogen synthesis contributed to prevent an increase in EGP after fructose 
ingestion in all three groups. The failure of an increased glucose synthesis from fructose to enhance overall EGP 
in NIDDM mirrors the observation by other investigators that inhibition of gluconeogenesis in NIDDM patients 
did not decrease EGP and plasma glucose concentrations [30]. Together, these observations indicate that EGP 
also remains constant in obese non-diabetic subjects and in obese patients with NIDDM when gluconeogenesis is 
stimulated at the substrate level. 
Incidentally, fructose concentrations were somewhat higher in obese compared to lean subjects. We have no 
obvious explanation for this difference. Although the fructose dose was normalized for FFM, differences in 
blood volume may possibly account for this variation. Alternatively, first pass hepatic extraction of fructose may 
be decreased in obese patients; however, their EGP was normal both in the basal state and during fructose 
administration. In all three groups of subjects, fructose concentration did not significantly change during the 3rd 
hour of administration, suggesting that hourly fructose absorption was roughly equal to hourly fructose ingestion 
by this time. 
Glucagon plays a central role in the regulation of EGP. However, the autoregulation of EGP does not involve 
suppression of glucagon secretion because it is also present when glucagon concentrations are maintained 
constant by means of infusions of somatostatin and exogenous glucagon [2, 5]. Hyperglucagonaemia is 
nonetheless, frequently found in NIDDM patients, and many stimulate gluconeogenesis and EGP from an 
increased supply of endogenous gluconeogenic precursors. In order to further delineate the effects of 
hyperglucagonaemia on substrate-induced EGP, healthy subjects were further studied during ingestion of 
fructose with hyperglucagonaemia or during hyperglucagonaemia alone. In lean subjects, ingestion of 13C 
fructose during moderate hyperglucagonaemia led to a 20 % increase in EGP. The subsequent rise in blood 
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glucose level was, however, modest, most likely due to a simultaneous increase in insulin secretion which 
stimulated peripheral glucose uptake, but may also have limited EGP. Glucagon alone failed to increase EGP, 
but induced a slight rise in plasma glucose and insulin. This stimulation of insulin secretion has been shown to 
be responsible for the inhibition of a glucagon-induced rise in hepatic glucose output [31]. It appears unlikely 
that glucagon increased EGP merely by increasing fructose conversion into glucose because fructose enters the 
gluconeogenic pathway at the level of the triose-phosphates, thus by-passing the major gluconeogenic steps 
controlled by glucagon. Non-oxidative fructose disposal, which corresponds to gluconeogenesis and de novo 
lipogenesis was not affected by glucagon. Glucagon may have increased the former while decreasing the latter, 
but such an effect is also unlikely because de novo lipogenesis is an energy-requiring process [32] and energy 
expenditure was not reduced by glucagon. EGP is the result of several processes including a) the glycogenolytic 
and gluconeogenic pathways which both contribute to the intrahepatic glucose-6-phosphate pool, b) glycogen 
synthesis and hydrolysis of glucose-6-phosphate, which together account for glucose-6-ρhosphate disposal. The 
absence of alterations in plasma 13C glucose enrichment (which reflects the enrichment of intrahe-patic glucose-
6-phosphate) indicates that the relative rates of: a) 13C glucose synthesis from fructose and b) production of 
unlabelled glucose from glycogen and other gluconeogenic precursors did not change during 
hyperglucagonaemia. This points to an activation of net glucose-6-phosphate hydrolysis during 
hyperglucagonaemia which may be due to a stimulation of glucose-6-phosphatase or an inhibition of hepatic 
glucokinase activities. Alternatively, the inhibition by glucagon of glycogen synthase may have led to an 
increase in glucose-6-phosphate concentration, which may have increased the flux through glucose-6-
phosphatase. The hypothesis that glucagon may play a key role in channelling glucose-6-phosphate towards its 
systemic release at the expense of glycogen synthesis finds support in the literature. In fasted dogs, acute 
suppression of glucagon secretion by an infusion of somatostatin and insulin to maintain basal insulin 
concentrations decreased EGP and the conversion of gluconeogenic precursors to plasma glucose, while 
simultaneously increasing hepatic glycogen content [33]. A similar observation was made in dogs infused for 3 
days with stress hormones when glucagon infusion was abruptly stopped and the infusions of cortisol, 
epinephrine and growth hormone were continued [34]. Interestingly, neither fructose nor hyperglucagonaemia 
alone produced such effects. This indicates that fructose and glucagon produce two distinct alterations that act 
together to increase EGP. Fructose may have altered the intra-hepatic concentrations of one or several regulatory 
metabolites, while glucagon may have affected the activity of key enzymes on the pathways of glycogen 
synthesis and/or glucose-6-phosphate hydrolysis. It is furthermore tempting to speculate that these metabolic 
alterations were already present in obese NIDDM patients in the basal state, and were responsible for part or all 
of the enhanced EGP. 
We conclude that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in 
NIDDM, obese non-diabetic, and lean subjects; 2) in lean subjects, both an increased glucagonaemia and an 
enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without 
changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i.e. 
glycogenolysis + gluconeogenesis from non-fructose precursors). 
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